---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-409199"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2026-09-30T21:00:05+00:00"
generated_at: "2026-10-12T14:09:01.983629+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TScan Therapeutics signs separation agreements with CFO Amello and CMO Louis

## Summary
- CFO Jason A. Amello and CMO Chrystal Louis, M.D., MPH, will terminate employment on the earlier of Nov. 1, 2026 or the start of other employment.
- Amello remains entitled to previously disclosed termination payments plus an $85,000 milestone-based lump sum under the November 2025 retention program.
- Louis remains entitled to previously disclosed termination payments plus a $125,000 milestone-based lump sum under the 2025 Retention Program.
- During the transition, each executive’s base salary and applicable employee benefits will continue until the earlier of Nov. 1, 2026 or new employment.

## SEC filing metadata
- accession: 0001193125-26-409199
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2026-09-30T21:00:05+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312526409199/0001193125-26-409199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312526409199/d59998d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-409199
- JSON: https://secwatch.observer/filing/0001193125-26-409199.json
- Plain text: https://secwatch.observer/filing/0001193125-26-409199.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.